ASAyşe Çiğdem Sivrice

Ayşe Çiğdem Sivrice

*This is an algorithmically generated author record based on publicly available information.

Ayşe Çiğdem Sivrice has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Life-Threatening Recurrence of Paroxysmal Cold Hemoglobinuria in a Child During Influenza A Infection

    by İbRahim Cemal Maslak, Muhammed Burak Selver, Ömer Kaşkaya, Merve Bayrak Yıldırım, Ayşe Çiğdem Sivrice, Mahmut Keskin, Ebru Sagay, Ebru Yılmaz Keskin

    Cite this article as: Maslak İC, Selver MB, Kaşkaya Ö, et al. Life-threatening recurrence of paroxysmal cold hemoglobinuria in a child during influenza A infection. Turk Arch Pediatr. 2024;59(4):419-421.


  • Open Access

    Multidisciplinary Management of Pediatric Hepatoblastoma: A 20-Year Single-Center Experience

    by Funda Tayfun Küpesiz, Ayşe Nur Akınel, Hilal Akbaş, Çiğdem Sivrice, Gülen Tüysüz Kintrup, Güngör Karagüzel, Mustafa Melikoğlu, Mustafa Tekinalp Gelen, Bülent Aydınlı, Alphan Küpesiz, et al.

    Background: Hepatoblastoma is rare cancer that responds well to risk-based chemotherapy, and surgical treatment is needed to achieve complete remission and satisfactory survival rates in hepatoblastoma patients. In this study, we evaluated the clinical features and treatment outcomes of pediatric hepatoblastoma patients treated in our clinic. Methods: Eighteen patients with hepatoblastoma who were treated and followed up in our center between June 1999 and June 2020 were analyzed retrospectively. All patients were evaluated by a multidisciplinary team and managed using a risk-based protocol (SIOPEL-1 and SIOPEL-3). Results: The patients’ mean age at diagnosis was 38.33 ± 52.34 months. Sixteen patients (89%) received neoadjuvant chemotherapy, and 2 patients (11%) who underwent complete mass excision at diagnosis received adjuvant chemotherapy. After neoadjuvant therapy, the tumor was completely resected in 8 patients (45%), while liver transplantation was performed in 6 patients (34%) because complete resection of the tumor was not possible. Two patients died before surgical treatment. One patient relapsed with lung metastasis after salvage chemotherapy. She is alive without disease at 64 months. The mean follow-up time was 59.3 ± 49.8 months; 5-year overall and disease-free survival rates were 88.9% and 80.8%, respectively. The 5-year overall survival rate was 100% for both liver transplant and resected patients, whereas 5-year disease-free survival was lower in transplant patients (75% vs 100%, P < .001). Conclusion: Multidisciplinary follow-up is especially important for patients who may need liver transplantation. Some patients may benefit from new treatment options such as radiofrequency ablation and cyberknife treatment. Cite this article as: Tayfun Küpesiz F, Akınel AN, Akbaş H, et al. Multidisciplinary management of pediatric hepatoblastoma: A 20-year single-center experience. Turk J Gastroenterol. 2022;33(12):1069-1078.


  • Open Access

    Clinical Characteristics and Treatment Outcomes of Patients with Malignant Extracranial Germ Cell Tumors: A 20-Year Single-Center Experience

    by Funda Tayfun Küpesiz, Gülen Tüysüz, Ayşe Nur Akınel, Ayşegül Tekneci, Ayşe Çiğdem Sivrice, Mustafa Melikoglu, Hadice Elif Pestereli, Osman Alphan Küpesiz, Elif Güler